Significance of serum IL-17 level in patients with acute coronary syndrome before and after rosuvastatin treatment
10.3969/j.issn.1009-0126.2014.09.012
- VernacularTitle:瑞舒伐他汀干预前后急性冠状动脉综合征患者血清白细胞介素17的变化及意义
- Author:
Guotian ZHANG
;
Yongsheng CHEN
- Publication Type:Journal Article
- Keywords:
acute coronary syndrome;
interleukin-17;
antilipemic agents;
troponin
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2014;(9):935-937
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the significance of serum IL-17 level in patients with acute coronary syndrome (ACS ) before and after rosuvastatin treatment .Methods Forty-eight ACS patients served as group A and 30 stable angina pectoris patients served as group B in this study .T heir blood-lipid level and serum hs-CRP and myocardial enzyme levels were measured and the number of coronary artery branches with lesions was calculated .Their association with serum IL-17 level was analyzed .Patients in group A were treated with rosuvastatin .The serum IL-17 levels were compared in two groups before and 4 weeks after rosuvastatin treatment .Results The serum IL-17 level was significantly higher in group A than in group B before rosuvastatin treatment (34.41 ± 6 .37 ng/L vs 15 .18 ± 3 .11 ng/L ,P<0 .05) and significantly lower in group A 4 weeks after rosuvastatin treatment than before rosuvastatin treatment (16 .71 ± 4 .72 ng/L vs 34 .41 ± 6.37 ng/L ,P<0 .05) .No significant difference was found in serum IL-17 level between the two groups after rosuvastatin treatment (P>0 .05) .Multivariate regression analysis showed that the serum hs-CRP and troponin level and the number of coronary artery branches with lesions were positively related with the serum IL-17 level (P=0 .012 ,0 .008 ,0 .000) .Conclusion Serum IL-17 level in ACS patients can partly reflect the severity of ACS .Early treatment of ACS with rosuvas-tatin can reduce the inflammatory reactions and serum IL-17 level ,and is of great significance in stabilizing the coronary plaques and reducing the incidence of ACS .
